RPG Life Sciences Limited
NSE: RPGLIFE
Employs 1,366 permanent employees and workers, 2.6% on the year before, as filed for the year to 31 Mar 2026 on a group basis. Revenue in the quarter to 31 Dec 2024 was ₹173 cr.
Headcount
Annual, from the BRSR filed with NSE (as of 31 March each year)
| As of | Scope | Permanent | Change (%) | Contract / other | Change (%) |
|---|---|---|---|---|---|
| 31 Mar 2023 | Standalone | 1,214 | — | 402 | — |
| 31 Mar 2024 | Standalone | 1,270 | 56(4.6%) | 468 | 66(16.4%) |
| 31 Mar 2025 | Standalone | 1,331 | 61(4.8%) | 447 | −21(4.5%) |
| 31 Mar 2026 | Group⚠ | 1,366 | 35(2.6%) | 646 | 199(44.5%) |
- ⚠The reporting scope changed from the previous period, so the two are not comparable.
Permanent = permanent employees + permanent workers, as defined in SEBI's BRSR. "Standalone" figures cover the listed company alone and exclude its subsidiaries.
Financials (₹ cr)
| Period | Revenue (₹ cr) | Change (%) | Employee cost (₹ cr) | Change (%) | Net profit (₹ cr) | Change (%) | Flags |
|---|---|---|---|---|---|---|---|
| Quarter ended 31 Dec 2024 | 173 | 1(0.3%) | 29 | −4(13.2%) | 35 | 31(731.7%) | |
| Quarter ended 30 Sept 2024 | 172 | 7(4.1%) | 33 | 0(1.1%) | 4 | −23(84.3%) | |
| Quarter ended 30 Jun 2024 | 165 | 38(30.3%) | 33 | 1(2.1%) | 27 | 14(102.1%) | |
| Quarter ended 31 Mar 2024 | 127 | −27(17.4%) | 32 | −2(4.8%) | 13 | −13(50.0%) | |
| Quarter ended 31 Dec 2023 | 154 | 0(0.1%) | 34 | 0(0.3%) | 26 | 1(2.3%) | |
| Quarter ended 30 Sept 2023 | 154 | 6(3.9%) | 34 | 1(2.4%) | 26 | 4(17.0%) | |
| Quarter ended 30 Jun 2023 | 148 | 29(24.7%) | 33 | −1(2.9%) | 22 | 12(113.5%) | |
| Quarter ended 31 Mar 2023 | 118 | −12(9.3%) | 34 | 5(19.4%) | 10 | −9(45.8%) | |
| Quarter ended 31 Dec 2022 | 131 | 27(25.8%) | 28 | 3(13.0%) | 19 | 12(154.1%) | ⚠ |
| Quarter ended 31 Mar 2022 | 104 | −12(10.2%) | 25 | −1(2.0%) | 8 | −7(48.6%) | ⚠ |
| Quarter ended 31 Dec 2021 | 116 | 3(2.6%) | 26 | −0(0.8%) | 15 | −1(7.1%) | ⚠ |
| Quarter ended 30 Sept 2021 | 113 | 5(4.2%) | 26 | 2(9.2%) | 16 | 2(16.0%) | ⚠ |
| Quarter ended 30 Jun 2021 | 108 | 15(16.6%) | 24 | 1(3.5%) | 14 | 7(96.2%) | ⚠ |
| Quarter ended 31 Mar 2021 | 93 | −15(13.8%) | 23 | −2(6.4%) | 7 | −6(46.2%) | ⚠ |
| Quarter ended 31 Dec 2020 | 108 | 10(10.8%) | 24 | −0(0.2%) | 13 | 2(15.4%) | ⚠ |
| Quarter ended 30 Sept 2020 | 97 | 5(6.0%) | 24 | 0(1.7%) | 11 | 2(23.1%) | ⚠ |
| Quarter ended 30 Jun 2020 | 92 | 3(3.4%) | 24 | 0(1.4%) | 9 | 6(204.0%) | ⚠ |
| Quarter ended 31 Mar 2020 | 89 | −10(10.0%) | 24 | −1(5.0%) | 3 | −7(69.5%) | ⚠ |
| Quarter ended 30 Sept 2019 | 98 | 4(4.7%) | 25 | 2(7.8%) | 10 | 1(17.0%) | ⚠ |
| Quarter ended 30 Jun 2019 | 94 | 25(36.7%) | 23 | 3(16.1%) | 8 | 7(442.2%) | ⚠ |
| Quarter ended 31 Mar 2019 | 69 | −22(24.4%) | 20 | −4(16.8%) | 2 | −4(70.8%) | ⚠ |
| Quarter ended 31 Dec 2018 | 91 | 0(0.5%) | 24 | 0(0.3%) | 5 | 3(144.4%) | ⚠ |
| Quarter ended 30 Sept 2018 | 91 | 7(8.4%) | 24 | −1(4.1%) | 2 | 1(72.8%) | ⚠ |
| Quarter ended 31 Mar 2018 | 83 | — | 25 | — | 1 | — | ⚠ |